Adrenal tumors occur in one or both adrenal glands, which are endocrine organs located on the top of kidneys. Each adrenal gland has two parts, with the outer part (cortex) producing aldosterone, cortisol, and/or androgens that impact salt and potassium balance, metabolism, and sexual characteristics, respectively, when overly excreted in patients with hyperaldosteronism, Cushing’s Syndrome, or adrenocortical carcinoma, and the inner part (medulla) producing catecholamines which affect heart rate, blood pressure and/or cause other systemic sympathetic symptoms when overly excreted by pheochromocytoma and paraganglioma (PPGLs). Of note, paraganglioma develops outside the adrenal glands but develops from the identical or similar type of cells that pheochromocytomas do and consequently in the scope as well. With endocrine function, even benign adrenal tumors can be bothering or even life-threatening, and require evaluations and corresponding management. Primary malignancies include adrenocortical carcinoma and malignant PPGLs, with poor prognoses and unsatisfying reactions to first-line therapies. An improved understanding of the genetic, molecular, and cellular changes lead to novel ideas and ultimately clinical improvements in strategies of screening, evaluating and treating adrenal tumors, and managing systemic impacts and risks of patients with functional and/or malignant adrenal tumors.
Screening, evaluation, surgical removal, peri-operation management, metastasis tracking, and treatment for adrenal tumors are fundamental demands for clinicians but challenges exist in those procedures. Consequently, relevant new techniques or strategies are encouraged to be presented in this Research Topic. Moreover, a comprehensive understanding of the underlying genetic and molecular images of adrenal tumors is of urgent need, which may aid us in identifying potential therapeutic targets and developing new treatments. Articles should be contributed as Original Research, Systematic Review, Methods, Review, Mini Review, Hypothesis and Theory, Perspective, Clinical Trial, Opinion, Editorial, Technology and Code.
We welcome manuscripts that focus on but are not limited to:
• Clinical advances (new strategies/new techniques/clinical studies) in screening or functional evaluation of adrenal tumors including but not limited to adrenocortical adenoma, adrenocortical carcinoma, pheochromocytoma, and paraganglioma.
• Clinical advances in treatment, including surgical techniques, pharmacological therapy, as well as preoperative, intraoperative, and postoperative managements for adrenal tumors.
• Observative/genetic/multiomic/bioinformatical studies in adrenal tumors.
• Molecular mechanisms of adrenal tumors, including tumorigenesis, progression or metastasis.
• Basic or preclinical investigations on diagnostic and prognostic evaluation of adrenal tumors including but not limited to biochemical detection and image detection of adrenal tumors using imageomics or functional imaging like molecular-biochemical PET-CT.
• Basic or preclinical investigations of novel treatments or potential therapeutic molecules for benign or malignant/metastatic adrenal tumors, including but not limited to targeted therapies and comprehensive therapies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Adrenal tumors occur in one or both adrenal glands, which are endocrine organs located on the top of kidneys. Each adrenal gland has two parts, with the outer part (cortex) producing aldosterone, cortisol, and/or androgens that impact salt and potassium balance, metabolism, and sexual characteristics, respectively, when overly excreted in patients with hyperaldosteronism, Cushing’s Syndrome, or adrenocortical carcinoma, and the inner part (medulla) producing catecholamines which affect heart rate, blood pressure and/or cause other systemic sympathetic symptoms when overly excreted by pheochromocytoma and paraganglioma (PPGLs). Of note, paraganglioma develops outside the adrenal glands but develops from the identical or similar type of cells that pheochromocytomas do and consequently in the scope as well. With endocrine function, even benign adrenal tumors can be bothering or even life-threatening, and require evaluations and corresponding management. Primary malignancies include adrenocortical carcinoma and malignant PPGLs, with poor prognoses and unsatisfying reactions to first-line therapies. An improved understanding of the genetic, molecular, and cellular changes lead to novel ideas and ultimately clinical improvements in strategies of screening, evaluating and treating adrenal tumors, and managing systemic impacts and risks of patients with functional and/or malignant adrenal tumors.
Screening, evaluation, surgical removal, peri-operation management, metastasis tracking, and treatment for adrenal tumors are fundamental demands for clinicians but challenges exist in those procedures. Consequently, relevant new techniques or strategies are encouraged to be presented in this Research Topic. Moreover, a comprehensive understanding of the underlying genetic and molecular images of adrenal tumors is of urgent need, which may aid us in identifying potential therapeutic targets and developing new treatments. Articles should be contributed as Original Research, Systematic Review, Methods, Review, Mini Review, Hypothesis and Theory, Perspective, Clinical Trial, Opinion, Editorial, Technology and Code.
We welcome manuscripts that focus on but are not limited to:
• Clinical advances (new strategies/new techniques/clinical studies) in screening or functional evaluation of adrenal tumors including but not limited to adrenocortical adenoma, adrenocortical carcinoma, pheochromocytoma, and paraganglioma.
• Clinical advances in treatment, including surgical techniques, pharmacological therapy, as well as preoperative, intraoperative, and postoperative managements for adrenal tumors.
• Observative/genetic/multiomic/bioinformatical studies in adrenal tumors.
• Molecular mechanisms of adrenal tumors, including tumorigenesis, progression or metastasis.
• Basic or preclinical investigations on diagnostic and prognostic evaluation of adrenal tumors including but not limited to biochemical detection and image detection of adrenal tumors using imageomics or functional imaging like molecular-biochemical PET-CT.
• Basic or preclinical investigations of novel treatments or potential therapeutic molecules for benign or malignant/metastatic adrenal tumors, including but not limited to targeted therapies and comprehensive therapies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
